Stocklytics Platform
Asset logo for symbol THTX
Theratechnologies
THTX65
$1.20arrow_drop_down0.82%-$0.01
Penny Stock
Asset logo for symbol THTX
THTX65

$1.20

arrow_drop_down0.82%

Performance History

Chart placeholder
Key Stats
Open$1.21
Prev. Close$1.22
EPS-0.04
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$55.63M
PE Ratio-
LOWHIGH
Day Range1.19
1.22
52 Week Range0.88
2.58
Ratios
Revenue-
EPS-0.04

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Theratechnologies (THTX)

Theratechnologies Inc. (THTX) is a pharmaceutical company that specializes in the research, development, and commercialization of therapeutic products for the treatment of various medical conditions. The company's primary focus is on the field of HIV/AIDS, with a portfolio of products targeting this disease. With a strong commitment to innovation and a dedication to improving patient outcomes, Theratechnologies has become a leader in the field of HIV/AIDS therapeutics. The company is headquartered in Montreal, Canada, and operates in various markets around the world.
One of the key factors to consider when evaluating a company's stock is its price history. Taking a look at Theratechnologies' stock price history, we can see that it has experienced both ups and downs over the years. The stock has had periods of significant growth, followed by periods of decline. This volatility can be attributed to various factors, such as changes in the market, industry trends, and company-specific events.
In recent news, Theratechnologies announced the launch of a new product that has the potential to significantly improve patient outcomes. The company's latest innovation is expected to address a key unmet medical need in the field of HIV/AIDS. This news has generated a lot of interest among investors and industry experts, as it demonstrates Theratechnologies' ongoing commitment to innovation and its ability to meet the evolving needs of patients.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Paul Lévesque
Headquarters
Montreal
Employees
144
Exchange
NASDAQ
add Theratechnologies to watchlist

Keep an eye on Theratechnologies

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Theratechnologies 's (THTX) price per share?

The current price per share for Theratechnologies (THTX) is $1.2. The stock has seen a price change of -$0.01 recently, indicating a -0.83% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Theratechnologies (THTX)?

For Theratechnologies (THTX), the 52-week high is $2.58, which is 115% from the current price. The 52-week low is $0.88, the current price is 36.36% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Theratechnologies (THTX) a growth stock?

Theratechnologies (THTX) has shown an average price growth of -6.03% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Theratechnologies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Theratechnologies (THTX) stock price performance year to date (YTD)?

As of the latest data, Theratechnologies (THTX) has a year-to-date price change of -28.99%. Over the past month, the stock has experienced a price change of -11.76%. Over the last three months, the change has been -9.09%. Over the past six months, the figure is -9.77%. Looking at a longer horizon, the five-year price change stands at -90.63%.
help

Is Theratechnologies (THTX) a profitable company?

Theratechnologies (THTX) has a net income of -$23.96M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.99% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 27.49% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 2.13%, providing insight into the company's sales performance and growth. The gross profit is $62.13M. Operating income is noted at -$10.63M. Furthermore, the EBITDA is $14.4M.
help

What is the market capitalization of Theratechnologies (THTX)?

Theratechnologies (THTX) has a market capitalization of $55.18M. The average daily trading volume is 1.2, indicating the stock's liquidity and investor engagement.

News

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
THERATECHNOLOGIES
EGRIFTA SV
SUPPLY DISRUPTION
FDA INSPECTION
CONTRACT MANUFACTURER
Sep 17, 2024

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

Theratechnologies annonce un risque d’interruption temporaire de l’approvisionnement d’EGRIFTA SVᴹᴰ au début de 2025
THERATECHNOLOGIES
EGRIFTA SVMD
SUPPLY INTERRUPTION
FDA INSPECTION
Sep 17, 2024

Theratechnologies annonce un risque d’interruption temporaire de l’approvisionnement d’EGRIFTA SVᴹᴰ au début de 2025

Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2024 et fera une mise à jour de ses activités
CALENDAR OF EVENTS
Jun 26, 2024

Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2024 et fera une mise à jour de ses activités

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
CALENDAR OF EVENTS
Jun 26, 2024

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
Jun 5, 2024

Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
CALENDAR OF EVENTS
HEALTH
TRADE SHOW
May 23, 2024

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Take Your Investments to a Whole New Level